title: The CCND1 G870A polymorphism and susceptibility to bladder cancer.
abstract: Published studies on the association between cyclin D1 (CCND1) G870A polymorphism and bladder cancer risk have yielded conflicting results. Thus, a systemic review and meta-analysis of published studies were performed to assess the possible association. All eligible studies of G870A polymorphism and bladder cancer risk were collected from the PubMed and the Cochrane Library. Statistical analyses were performed by Review Manager 5.0 and Stata 11.0. Significant association between G870A polymorphism and bladder cancer susceptibility was found under recessive model in overall population (OR = 1.21, 95% CI 1.01-1.45, P = 0.04). When stratifying for the race, our analysis suggested that CCND1 G870A was associated with bladder cancer risk in Asians when using homogeneous codominant (OR = 1.72, 95% CI 1.34-2.20, P < 0.0001), recessive (OR = 1.46, 95% CI 1.21-1.77, P < 0.0001), dominant (OR = 1.36, 95% CI 1.10-1.69, P = 0.004), and allelic models (OR = 1.30, 95% CI 1.15-1.47, P < 0.0001) to analyze the data. However, no significant associations were found in Caucasians. After stratifying the studies by control source, G870A polymorphism was significantly associated with bladder cancer risk under recessive model (OR = 1.31, 95% CI 1.03-1.67, P = 0.03) in hospital-based case-control studies, but not in population-based case-control studies. This meta-analysis suggested that G870A polymorphism most likely contributes to increased susceptibility to bladder cancer in the overall population, hospital-based case-control studies, and Asians.
authors.affiliation: Department of Urology, Tianjin Key Lab of Urology, Second Affiliated Hospital of Tianjin Medical University, Tianjin, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.forename: Fei
authors.initials: F
authors.lastname: Luo
authors.forename: Hongtuan
authors.initials: H
authors.lastname: Zhang
authors.forename: Liang
authors.initials: L
authors.lastname: Li
authors.forename: Yong
authors.initials: Y
authors.lastname: Xu
mesh_terms: D000483:Alleles; D016022:Case-Control Studies; D019938:Cyclin D1 / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000208:ethnology / Q000235:genetics*
chemical_list: D019938:Cyclin D1
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2569-78
references.pmid: 16284380
references.citation: PLoS One. 2012;7(5):e36813
references.pmid: 22606291
references.citation: Tumour Biol. 2012 Oct;33(5):1467-76
references.pmid: 22528945
references.citation: Asian Pac J Cancer Prev. 2012;13(10):5023-5
references.pmid: 23244103
references.citation: Tumour Biol. 2012 Dec;33(6):2189-99
references.pmid: 23001925
references.citation: Lancet. 1993 Oct 30;342(8879):1087-8
references.pmid: 8105314
references.citation: BMC Cancer. 2009 Dec 15;9:443
references.pmid: 20003537
references.citation: PLoS One. 2013;8(3):e58170
references.pmid: 23472153
references.citation: Oncogene. 1995 Sep 7;11(5):1005-11
references.pmid: 7675441
references.citation: Genes Chromosomes Cancer. 1998 May;22(1):66-71
references.pmid: 9591636
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9871-5
references.pmid: 7937908
references.citation: BMC Immunol. 2012 Mar 21;13:14
references.pmid: 22435969
references.citation: J Urol. 1998 Sep;160(3 Pt 1):897-900
references.pmid: 9720584
references.citation: Carcinogenesis. 2002 Feb;23(2):257-64
references.pmid: 11872630
references.citation: Cancer. 2008 Jun;112(11):2467-74
references.pmid: 18361427
references.citation: Toxicol Appl Pharmacol. 2008 Oct 15;232(2):203-9
references.pmid: 18640142
references.citation: Cancer. 1997 Feb 15;79(4):780-9
references.pmid: 9024716
references.citation: N Engl J Med. 1992 Mar 12;326(11):737-40
references.pmid: 1445507
references.citation: Br J Cancer. 1997;75(12):1788-92
references.pmid: 9192983
references.citation: DNA Cell Biol. 2010 Oct;29(10):611-7
references.pmid: 20575692
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: World J Surg. 2009 Jan;33(1):124-9
references.pmid: 19011936
references.citation: Carcinogenesis. 2004 May;25(5):729-34
references.pmid: 14688016
references.citation: APMIS. 2008 Apr;116(4):309-16
references.pmid: 18397466
references.citation: Chin J Physiol. 2011 Jun 30;54(3):196-202
references.pmid: 21789902
references.citation: DNA Cell Biol. 2010 Jul;29(7):349-56
references.pmid: 20380574
references.citation: Carcinogenesis. 2003 Oct;24(10):1645-50
references.pmid: 12896908
references.citation: Int J Cancer. 2002 Feb 10;97(5):671-8
references.pmid: 11807796